title: Effects of immobilized recombinant human bone morphogenetic protein-2/succinylated type I atelocollagen on cellular activity of ST2 cells.
abstract: The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) to induce ectopic bone formation requires a carrier. Type I atelocollagen, a biomaterial with a porous structure, excellent operational features, and biocompatibility, is an effective carrier for rhBMP-2. However, the conventionally used lyophilized rhBMP-2/collagen mixture does not necessarily give adequate bone-induction effect. In the present study, we examined the effect of immobilizing rhBMP-2 to type I atelocollagen on the cellular activity of ST2 cells. The following results were obtained: (1) rhBMP-2 was effectively immobilized to succinylated type I atelocollagen, indicating the usefulness of succinylated type I atelocollagen in immobilization; (2) studies of alkaline phosphatase activity confirmed the effectiveness of rhBMP-2 immobilized on succinylated atelocollagen in augmenting cellular activity.
authors.affiliation: Department of Oral Pathology and Medicine, Graduate School of Medicine and Dentistry, Okayama University, 2-5-1 Shikata-Cho, Okayama City 700-8525, Japan. tsuji@md.okayama-u.ac.jp
authors.forename: Hidetsugu
authors.initials: H
authors.lastname: Tsujigiwa
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Nagatsuka
authors.forename: Mehmet
authors.initials: M
authors.lastname: Gunduz
authors.forename: Andrea
authors.initials: A
authors.lastname: Rodriguez
authors.forename: Rosario S
authors.initials: RS
authors.lastname: Rivera
authors.forename: Racquel Z
authors.initials: RZ
authors.lastname: Legeros
authors.forename: Miho
authors.initials: M
authors.lastname: Inoue
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Nagai
mesh_terms: D000469:Alkaline Phosphatase / Q000737:chemistry / Q000378:metabolism; D000818:Animals; D001672:Biocompatible Materials / Q000737:chemistry*; D015153:Blotting, Western; D001854:Bone Marrow Cells / Q000166:cytology / Q000187:drug effects*; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000737:chemistry* / Q000494:pharmacology; D001842:Bone and Bones / Q000378:metabolism; D002460:Cell Line; D003094:Collagen / Q000737:chemistry*; D024042:Collagen Type I / Q000737:chemistry; D004058:Diffusion; D004305:Dose-Response Relationship, Drug; D004591:Electrophoresis, Polyacrylamide Gel; D006801:Humans; D051379:Mice; D011994:Recombinant Proteins / Q000737:chemistry* / Q000494:pharmacology; D013386:Succinates / Q000737:chemistry; D013997:Time Factors; D016212:Transforming Growth Factor beta / Q000737:chemistry* / Q000494:pharmacology
chemical_list: C525718:BMP2 protein, human; D001672:Biocompatible Materials; C525719:Bmp2 protein, mouse; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D024042:Collagen Type I; D011994:Recombinant Proteins; D013386:Succinates; D016212:Transforming Growth Factor beta; C059821:atelocollagen; C499469:recombinant human bone morphogenetic protein-2; D003094:Collagen; D000469:Alkaline Phosphatase